VIDEO: ‘Buckle up’ for new anti-obesity medications coming down the pipeline
Click Here to Manage Email Alerts
DENVER — The development of several new anti-obesity medications could improve availability for patients, according to a speaker at the Obesity Medicine Association’s conference.
“Folks, I got to tell you, buckle up because the types of exciting new therapies that are in the pipeline right now ... it’s just truly unprecedented,” Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, the medical director and president of the Louisville Metabolic and Atherosclerosis Research Center and chief science officer of the Obesity Medicine Association, said.
Bays pointed out that more drugs will create competition “in addition to helping more patients.”
“When you create competition, that may have the potential to increase access,” he said. “In addition to that, some of the drugs that we are developing now or some of the drugs that are currently being used ultimately may become generic, which should create even more accessibility.”
Reference:
- Bays H. AOMs in the pipeline: A clinical trialist perspective. Presented at: Obesity Medicine 2024. April 24-28, 2024; Denver.